Bone Health Interview

Quote

Anonymous

Guest
Can anyone provide an insight in the Bone Health primary care sales position? What else are you selling if anything? Compensation? Base and commission? History of drugs? bad, good etc. Please only serious replies.
 












Serious reply...

Please think long and hard about this division.

Terrible terrible micro management that is driving away very good people. What we were told and what has transpired are two totally different things.

The leadership has changed our action plan every 60 days or so since launch. This is Amgen's first time in primary care and they have failed in launching a wonderful drug. We were hired based on our resumes and then were instructed to work in a completely different direction.

We are losing ground in a share of voice aspect as well as a constantly changing focus.

If it is the only opportunity you have I would say proceed with extreme caution.

Micro management is not working yet they continue to force it upon us. It is difficult for people to change and the managers don't seem to have the ability to adapt to a different style. If you are looking for an alternative to the way larger pharma companies operate, this is not it.

Salary and bonus are prob a 125k package but goals make it difficult for the majority of the force to attain. Poorly lead division...bottom line and it does not seem to be changing anytime soon.

I am sure you will get smart ass replies as this is common on this site. Try to sort out the mature vs the other.

Hope this helps. Wish I was given this insight 2 years ago.

Smart ass replies soon to follow........trust me
 






























Anonymous said:
If you get hired you will get laid off very soon.
Click to expand...

Good point. Check this out

Growth in the use of prescription drugs continues to slow



By Linda A. Johnson THE ASSOCIATED PRESS


TRENTON, N.J. — Spending on prescription drugs in the U.S. grew relatively slowly last year as fewer people started new prescriptions and more prescriptions were filled with cheaper generics, an industry study shows.

Americans and their insurers spent $307.4 billion on prescription drugs in 2010, up just 2.3 percent from the previous year. Growth had already slowed to 5.1 percent in 2009, from as much as 13 percent a year earlier in the decade.

The study released last month by the IMS Institute for Healthcare Informatics, an arm of health data firm IMS Health, shows the volume of prescription medicines that Americans used also increased at historically low levels.

That’s bad news for brand-name pharmaceutical companies — but may also be for doctors and patients.

The number of visits to doctors’ offices declined 4.2 percent in 2010, to 1.54 billion, according to the study. That downward trend began in mid-2009, as the employment rate remained stubbornly high and more people lost health insurance.

Pharmacies filled 0.5 percent fewer prescriptions in 2010 than in 2009 for pills, capsules and nasal spray medications — about 60 percent of total spending on medications. For medicines that are injected or infused, total volume rose even less, just 0.2 percent.

“These trends combined to make 2010 the second-lowest sales growth period ever measured by IMS,” said Michael Kleinrock, the institute’s director of research development. “The lowest was 2008.”

The number of patients starting new medicines for chronic illnesses in 2010 also declined. It fell by 3.4 million people from 2009, to 68.8 million.

“This has the potential to impact patients’ health,” Kleinrock said. “If they’re delaying necessary care, that could be pretty bad for their health.”

The chronic illness section of the report analyzed medication used for 17 conditions that account for nearly 70 percent of prescriptions for chronic conditions and nearly 40 percent of all prescriptions. Those illnesses include high blood pressure and cholesterol, Alzheimer’s disease, diabetes, depression, HIV, osteoporosis and attention deficit disorder.

In dollars, spending on chronic medications accounts for almost half of total spending, and big pharmaceutical companies have invested heavily in developing these medicines to ensure a steady revenue stream for many years.

That makes the drop in new patients starting chronic medicines a worrying trend for brand-name pharmaceutical companies, combined with the increasing difficulty of creating new drugs and with pricing pressure from insurance programs and encroachment by generic drug makers.

Spending on name-brand drugs fell 0.7 percent in 2010.

The use of generic drugs, which can cost a fraction of the price of brand-name medications, is skyrocketing, according to the IMS report. In 2010, generics accounted for 78 percent of all retail prescriptions filled, up from 63 percent in 2006.

Spending on unbranded generics rose 21.7 percent last year from 2009.

The generic surge helped insured patients’ wallets a bit, as the average prescription co-payment dipped 20 cents, to $10.73.

The average cost of pills and inhaled medicines declined 0.1 percent last year, while the average cost of intravenous medicines rose 5.7 percent.

IMS found 63 percent of prescriptions filled last year were covered by commercial insurance, down from 66 percent in 2006, while the share of prescriptions filled under Medicare or Medicaid jumped from 22 percent to 30 percent over that period.

Meanwhile, 44 new brand-name drugs were launched last year, many for rare disorders or with a mechanism of action similar to existing treatments. Those constraints limited average spending on the new products as patients and payers made careful choices based on economics.
 






Anonymous said:
Serious reply...

Please think long and hard about this division.

Terrible terrible micro management that is driving away very good people. What we were told and what has transpired are two totally different things.

The leadership has changed our action plan every 60 days or so since launch. This is Amgen's first time in primary care and they have failed in launching a wonderful drug. We were hired based on our resumes and then were instructed to work in a completely different direction.

We are losing ground in a share of voice aspect as well as a constantly changing focus.

If it is the only opportunity you have I would say proceed with extreme caution.

Micro management is not working yet they continue to force it upon us. It is difficult for people to change and the managers don't seem to have the ability to adapt to a different style. If you are looking for an alternative to the way larger pharma companies operate, this is not it.

Salary and bonus are prob a 125k package but goals make it difficult for the majority of the force to attain. Poorly lead division...bottom line and it does not seem to be changing anytime soon.

I am sure you will get smart ass replies as this is common on this site. Try to sort out the mature vs the other.

Hope this helps. Wish I was given this insight 2 years ago.

Smart ass replies soon to follow........trust me
Click to expand...

Very well said. I second everything here.
 




































Top Bottom
Back
Quote